Dipeptidyl peptidase-4 inhibitors (DPP4i) improve glycemic control by increasing the serum levels of glucagon-like peptide 1 (GLP-1) and exhibit a neural effect in CV composite outcomes, that are clinically widely prescribed as second-line agents in the management of hyperglycemia for patients with T2DM [13, 14]. Here, DPP4 is linked to type 2 diabetes mellitus.